



The New Era Drug: Dostarlimab Having Effective Clinical Trial & Combination Clinical Therapies

Shashank Patel^{1*}, Anupama Singh², Vipin Kesharwani³, Shailesh Pathak⁴, Pankaj Jaiswal⁵, Asad Farooqi⁶

Abstract

Dostarlimab is a PD-1 monoclonal antibody used to treat adult patients with advanced or recurrent endometrial cancer who have progressed during or after prior therapy with a platinum-containing regimen and who have a mismatch repair defective (DMMR) mutation. Due to their outstanding abilities to stimulate the immune system's responses to cancer cells, such immunotherapies as immune checkpoint inhibitor therapy, monoclonal antibody therapy, and chimeric antigen T-cell therapy have drawn a lot of attention. This indication received fast approval based on the rate of tumour response and the length of the response, as evaluated by an FDA-approved test. Dostarlimab, a monoclonal antibody against the programmed cell death protein (PD-1) that has shown to completely (100%) cure patients with colorectal cancer, has enchanted the medical community in this period of rapid advancement. Dostarlimab has also demonstrated encouraging results in the treatment of breast cancer, melanoma, head and neck cancer, endometrial cancer, and ovarian cancer. This clinical trial demonstrated that it is possible to tailor therapy to a tumor's genetic makeup. Patients with pancreatic and stomach malignancies are now being enrolled in this research trial, which is still accepting new participants. This review's main objectives are to analyse the available information on dostarlimab and investigate the potential of mono- and combination therapy.

Key word: - Dostarlimab, Immunotherapies, Clinical Trails, Monoclonal antibody, T-cell

DOI Number: 10.4704/nq.2022.20.14.NQ88012

Neuro Quantology 2022; 20(14):86-96

Introduction

Despite decades of research in this area, cancer is still one of the deadly diseases that humanity has ever experienced, and it is still a major health issue that causes more than 10 million deaths annually [1]. There have been many different types of treatment implemented, including chemotherapy, radiotherapy, surgery, and immunotherapy. The extent and possibilities of immune-oncology, the most recent area of research in this discipline, have not yet been fully explored. The US Food and Drug Administration approved the first immunotherapy drug, a carcinogenic cytokine known as interferon alpha'2, in 1986. (FDA).

IFN-a2 was initially licenced for the treatment Of hairy cell leukemia (HCL) after research shown that patients with advanced HCL responded to the drug with a high rate. IFN-a2 was given FDA approval in 1995 to be used as adjuvant therapy for melanoma that was stage IIB/III. Cancer immunotherapy tries to reactivate the immune system, which tumour cells have in many ways inhibited. Numerous cutting-edge immunotherapy techniques are being developed to treat cancer or to reduce the cytotoxic side effects brought on by various cancer medications. Because they target malignant stem cells and even metastatic disease when activated, immunotherapies have

***Corresponding Author:** - Shashank Patel

Address: -^{1, 2, 3} Maharishi School of Pharmaceutical Sciences, MUIT Lucknow U.P India.

E-mail:- shashankpatelmdi@gmail.com

⁴Shambhunath Institute of Pharmacy, Jhalwa, Prayagraj Uttar Pradesh U.P India

⁵IEC College of Engineering and Technology Great Noida, U.P India.

⁶Mahrishi College of Pharmacy Bharwari Kaushambi U.P India.

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Received:

Accepted:



the potential to treat even the smallest of tumours that may be inaccessible to surgeons. The creation of cancer vaccines, which have showed promise in reducing tumour growth but fall short in totally curing it, has also come under the spotlight as a result of immunotherapy. There are also a number of antibody-based cancer treatments that either directly or indirectly connects to immuno therapy [2–5]. The Nobel Prize-winning work of Drs. Allison and Honjo [6], who discovered T-cell checkpoints like CTLA-4 and PD1, provided yet another remarkable insight into cancer immunotherapy. PD-1 is an inhibitory immunological check point receptor that recognizes activated T cells. By interacting with its ligands, programmed cell death ligands 1 and 2, PD-1 decreases the proliferative, cytokine-producing, and cytotoxic activity of activated effector T cells (PD-L1 & PD-L2). The overexpression of PD-L1 is one method used by tumour cells to evade the immune system and hinder cancer-specific immune responses. Research in both preclinical and clinical settings has demonstrated that therapies that bind to either the PD-1 receptor or ligand and successfully disrupt the receptor-ligand interaction can enhance antitumor immunity and increase patient survival in a variety of cancers [7]. Six PD-1 and PD-L1 inhibitors, collectively referred to as PD-L1, have thus far received FDA approval for clinical use. Due to the anti-PD-1 antibodies' competitive market, patients with cancer have a range of dosing regimens, disease-specific therapies, tolerance profiles, and financial options to select from. Dostarlimab, a monoclonal antibody, received accelerated clearance from the FDA on August 17, 2021, for use in treating people with advanced or recurrent DMMR endometrial cancer who have progressed after receiving treatment with a platinum-containing chemotherapy regimen in the past or present Figure 1. DMMR or MSI-H biomarker-positive tumours act abnormally in terms of DNA repair pathways. These cancers lack the genes necessary to correct any incorrect activity and sustain cell health. The PD-1 inhibitor dostarlimab showed sustained activity against DMMR tumours and, in 2022, reported a 100% remission rate for rectal cancer [8]. All patients carried DMMR, a mutation that occurs in between 5% and 10% of instances of rectal

cancer (this mutation is also present in endometrial, prostate, and bladder tumors). This clinical trial demonstrated that it is possible to match a tumor's genetic makeup with its therapeutic targets. Today, with other techniques, mAB-based immunotherapy is regarded as a crucial component of cancer treatment. These antibodies not only have the ability to target tumour cells but also to initiate robust immune responses that are anticancer. Future cancer treatments will be different thanks to the novel cancer treatment approaches that have been made possible by the adaptability of antibodies as a therapeutic platform.




Figure – 1. Timeline for the medicine Dostarlimab, from when it first showed promise in treating a small number of women with endometrial cancer until when it completely cured rectal cancer.

Relating to Medications

Dostarlimab, also known as TRS -042 or Jemperli, is a humanized monoclonal antibody of the IgG4 isotype made in mammalian Chinese hamster ovary (CHO) cells. It binds to the protein PD1 on T cells and prevents interactions with its ligands, PD-L1 and PD-L2, which trigger immune responses. During cancer treatment, the immunotherapy dostarlimab supports the body's own anti-tumor immune response. Depending on the cycle, it is administered every three to six weeks via intravenous infusion for more than 30 minutes. Each heavy chain of the antibody has a serine to proline substitution (S228P), which

helps to stabilize the disulfide connections between the two heavy chains and prevents the development of half-antibodies. Dostarlimab was made human by using the AnaptysBio SHM-XEL system to graft the heavy- and light-chain complementarity-determining regions onto the germ line variable region frameworks of their closest CONTACT human species orthologs, then affinities were matured via mammalian cell display and somatic hyper mutation. Dostarlimab was created by the business Anaptysbio in conjunction with Tesaro and was acquired by GlaxoSmithKline in 2019 [9, 10]. The final Jemperli™ product is a concentrate for infusion solution with dostarlimab as the active component and 500 mg. The additional ingredients include polysorbate 80, citric acid monohydrate, sodium chloride, trisodium citrate dihydrate, L-arginine hydrochloride, and water for injection. Although Dostarlimab's heavy chain participates in the interaction between PD-1 and Dostarlimab, steric inhibition of PD-L1 binding is mostly caused by the light chain. Dostarlimab alters the conformation of PD-1's BC, C'D, and FG loops to achieve high affinity. The residue R86 inside the C'D loop of PD-1 plays a crucial role in Dostarlimab binding by occupying the concave surface on the heavy chain through many interactions. The development of improved anti-PD-1 biologics or efficient cancer immunotherapy combination treatments may benefit from this high-resolution structure [11]. Dostarlimab was created to prevent the depletion of tumor-reactive T cells because IgG4 isotypes only slightly increase Fc-mediated effector functions such antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Fc binding has been utilized to demonstrate Dostarlimab ADCC activity's absence (in a Biacore analysis). It is known that an epitope within a target molecule may be a crucial part of a therapeutic antibody because antibodies that recognize various epitopes have different therapeutic efficacies, albeit the structural reason for this is yet unknown. PD-1 and PD-L1 antibodies inhibit cells in a similar way, however they recognize different antigenic epitopes. Monoclonal antibodies have long been a vital therapeutic tool due to their high specificity and affinities for their targets. Dostarlimab binds to the flexible loops of PD-1,

including the BC, C'D, and FG loops, differently than Pembrolizumab or Nivolumab, according to the high-resolution structure [11]. Dostarlimab was distinguished by numerous in vitro and in vivo studies, as well as preclinical effects, which allowed it to be classified as an experimental novel medication. When taken alone, dostarlimab does not significantly stimulate cytokines and exhibits no cross-reactivity with the mouse orthologous [9]. First, single-dose tests were conducted, then a 4-week repeat-dose study, and finally a 13-week repeat-dose research. Dostarlimab was shown to be equally hazardous to other anti-PD-1 antibodies at dosages of 30 and 100 mg/kg, according to all available evidence [12]. Tumor growth inhibition, a measure of dostarlimab anticancer potency, was associated with increased immune cell infiltration. These results demonstrate the potent anti-PD-1 receptor antagonist properties of dostarlimab, which call for more clinical trials in cancer patients. Dostarlimab elicits a mild immune response in a small percentage of cancer patients after one or more treatment cycles and has an anti-drug antibodies (ADA) rate of 2.5%, which is again comparable to other anti-PD-L1 medications. Due to its high product purity and method of administration, dostarlimab poses less of a risk of triggering immunological responses. Furthermore, there is currently no proof that the development of ADAs or ADAs that already exist have any impact on safety or efficacy assessments. According to these results, Dostarlimab is a brand-new, potent anti-PD-1 monoclonal antibody with a minimal likelihood of inducing immunogenic reactions [13]. Dostarlimab has demonstrated clinical activity in endometrial cancer (EC) and non-small cell lung cancer (NSCLC) regardless of MMR status, with a tolerability profile similar to other anti-PD-1 mAbs across tumor types. Data from the GARNET trial support reports that DMMR/MSI-H is a predictive biomarker of response to anti-PD-L1 agents.

Mechanism of Action

T-cells have the immune checkpoint receptor PD1, which blocks immunological responses that are directed specifically towards cancer. A Chinese hamster ovary cell is the source of the humanized IgG4 mAB, dostarlimab, which has a molecular weight of roughly 144 kDa. Cytokine



production and T-cell proliferation are inhibited by a binding between the PD-1 ligands (PD-L1 and PD-L2) and the PD-1 receptor on T-cells. PD-1 ligands are increased in several malignancies, and signalling along this route may help to decrease active T-cell immunity. Dostarlimab, a medication, enters the picture in this situation. It suppresses the activity of the programmed cell death receptor-1 (PD-1) and prevents receptors from interacting with PD-L1 and PD-L2, which in turn stimulates T cells and improves immunity all around. Dostarlimab has been shown to bind to PD-1 receptors in humans and cynomolgus monkeys with great affinity, as evidenced by the outcomes of flow cytometer and plasma on resonance experiments. Dostarlimab also demonstrated functional antagonist activity in a human CD4+ mixed lymphocyte response assay, increasing IL-2 production. Additionally, this assay demonstrated that dostarlimab activity was increased in the presence of TIM3 or LAG3 antibodies. The Dostarlimab showed enhanced activity in the presence of antibodies, but no appreciable cytokine release was seen from human PBMCs (peripheral blood mononuclear cells) [14].




Figure -2 -The activity of Dostarlimab in killing cancer cell, PD-1 inhibitor inhibit the connectivity of T-cell over expressing PD-1 cells.

Clinical Studies

A ground-breaking advancement in the treatment of cancer was made in June 2022. A medication during a clinical study

demonstrated for the first time in the history of science the total eradication of a tumour with no recurrence. Dostarlimab, a mAB-based medication, was tested for safety and effectiveness against locally advanced rectal cancer [15]. Stage III rectal cancer, also known as primary locally advanced rectal cancer, refers to respectable tumours that have lymph node involvement. These tumours are distinguished by their invasion and close proximity to the mesorectal fascia. Total mesorectal resection (TME) surgery, short-course irradiation, and intensive chemotherapy are the usual treatments for these forms of colorectal cancer. Positive outcomes from this group therapy include great survival rates and minimal recurrence rates. Additionally, a full resection of the tumour may be the most advantageous and preferable approach for control and survival in some circumstances with locally advanced tumours [16]. Radiation therapy and neo adjuvant chemotherapy are the main forms of treatment for locally advanced rectal cancer, which is then followed by surgical resection of the rectum. It has also been mentioned that a deficiency in mismatch repair is a contributing factor in some cases of rectal cancer. Single transmission repair-deficient colorectal cancer reacts to the programmed death 1 (PD-1) blockade in the context of metastatic illness, indicating that a checkpoint blockade may be useful in mismatch repair-deficient individuals. A prospective phase 2 study was started in individuals with mismatch repair-deficient stage II or stage III rectal adenocarcinomas by researchers working with GSK. Every three weeks for a total of six months, they received dostarlimab, a single-agent anti-PD-1 medication. Although normal surgery and chemo-radio therapy are to be performed after this treatment, patients who show a clinically complete response after receiving dostarlimab therapy won't need to have any of these procedures. This serves as the study's main endpoint as well. From the trial that was completed on a total of 12 patients who had successfully finished dostarlimab treatment and had also experienced a minimum of 6 months of follow-up, interim results were obtained. The results of 18F-fluorodeoxyglucose positron emission tomography, magnetic resonance imaging, biopsy, digital rectal examination, and



endoscopic evaluation demonstrated that all 12 patients (100%; 95% confidence interval, 74 to 100) had a complete clinical response with no evidence of preexisting tumour, progression, or recurrence. The analysis showed categorically that a single treatment, PD1, was extremely sensitive to locally progressed, mismatch repair-deficient rectal cancer and might produce favorable effects [17, 18]. However, a longer follow-up investigation is still required to support this claim. In a phase 1 nonrandomized clinical trial, dostarlimab was tested for anticancer efficacy and safety in patients with endometrial cancer that lacked adequate mismatch repair. Enrollment for patients with endometrial cancer with insufficient mismatch mutation repair started on May 8, 2017, and Part 1 of this ongoing open-label, multicenter single group research began on March 7, 2016. A total of 104 women with endometrial cancer that had deficient mismatch mutation repair were included in the study. Each patient received intravenous dostarlimab at a dose of 500 mg every three weeks for the first four doses and then 1000 mg every six weeks until the disease progressed, the treatment was stopped, or the patient withdrew. This study's specific goal was to assess the antitumor activity of dostarlimab in patients with advanced or recurrent DMMR (mismatch repair deficiency) endometrial cancer (EC) using the objective response rate (ORR), which was determined by a blinded independent central review (BICR) in accordance with RECIST standards. Radiographic examinations were carried out 12 weeks after the first dosage of dostarlimab was administered, then every 6 weeks (\pm 10 days) until month 12, and then every 12 weeks following that. The findings of this analysis on patients with platinum-based chemotherapy and dostarlimab immunotherapy-resistant recurrent or advanced DMMR EC who had progressed were associated with an ORR of 42.3% (95% CI, 30.6-54.6%) in nearly 30 patients, 29.6% in about 21 patients, and around 12.7% in 9 patients. The reactions lasted a long time, and after 11.2 months of follow-up, the median DOR was still not met. These findings represent the greatest body of information on DMMR EC treated with a PD-1 inhibitor to date, to the best of our knowledge [19, 20]. It is generally acknowledged that the

response rates with anti-PD-1 therapies appear to be better, as evidenced by the ORR range offered by single-agent therapies, which ranged from 13.5% (90% CI, 6.5-27.5%) for bevacizumab to 21-27.3% (95% CI, 15-42.8%) for paclitaxel prior to the introduction of anti-PD-1 therapies. However, cross-trial comparisons cannot be done. Dostarlimab may be useful in the treatment of patients with DMMR EC, despite the GARNET trial being a single-group study because of the antitumor activity seen in patients with DMMR EC. Dostarlimab displayed a significant ORR and a longer duration of response, highlighting its strong anticancer potential. Dostarlimab has a wide range of effects, but its dose schedule is what makes it special. After 12 weeks of first dostarlimab therapy, patients and caregivers benefit from this novel dose regimen, which may lead to fewer clinic visits and possibly lower healthcare expenses. Overall, the results of the GARNET study have shown that DMMR solid tumours that are not associated with endometrial malignancies can also exhibit lasting anticancer activity. Dostarlimab monotherapy was expedited for approval in the US as a treatment for recurrent/advanced DMMR solid tumours, according to the GARNET trial findings, as a result of the positive outcomes from earlier treatments. Furthermore, it has received conditional approval in Europe and accelerated approval in the USA for the treatment of DMMR/MSI-H and DMMR endometrial cancer, respectively, during and following platinum-based chemotherapy [21-23]. A comparable trial was also carried out to assess the efficacy of anti-PD-1/PD-L1 axis therapy in patients with incurable endometrial cancer. Researchers have recently attempted to investigate the effectiveness of dostarlimab in treating locally advanced cervical cancer (LACC). Dostarlimab as a consolidation therapy after chemotherapy may improve patients' progression-free survival rates, according to their hypotheses. A randomized, phase II, open-label research was designed as maintenance therapy for patients at high risk of LACC based on this justification. This ongoing study, which had about 132 participants when it started on June 28, 2019, is a randomized one. The outcomes of this investigation have not yet been released due to interim data [24, 25]. In a recent trial, 67 patients with advanced or recurrent



NSCLC who had previously received platinum-based chemotherapy participated in a phase 1, multi-center, open-label, two-part research GARNET cohort to examine the safety and antitumor efficacy of dostarlimab. Part 2 of the study, on the other hand, was conducted in two separate subparts: Part 2A evaluated the dose safety and Part 2B dealt with evaluating the clinical efficacy of the drug. Part 1 of the study was a dose escalation study and involved the evaluation of pharmacodynamics and pharmacokinetic characteristics of the drug at different doses of 1, 3, and 10 mg/kg. Dostarlimab anticancer efficacy in patients with recurrent or advanced NSCLC was assessed using the immuno-related objective response rate (irORR) and safety as the primary endpoints. Dostarlimab immunotherapy resulted in significant antitumor activity and long-lasting responses in all PD-L1 Tumor Proportion Score (TPS) status subgroups. Dostarlimab's safety profile in NSCLC was considered to be acceptable, with minimal to manageable toxicity, and to be consistent with that of the other medications that inhibit PD-L1. Four patients, or nearly 6% of the total research population, dropped out due to treatment-related TEAEs (treatment-emergent adverse effects) (TRAEs), while two patients died as a result of TEAEs that were not thought to be connected to dostarlimab therapy. In addition to the studies mentioned above that focused specifically on certain types of cancer, dostarlimab is also the subject of other trials intended for advanced solid tumours. In the phase 1 GARNET research (NCT02715284), it is being tested for safety and effectiveness in patients with advanced solid malignancies. Participants in Cohort F of the GARNET trial had non-endometrial solid tumors with DMMRs or DNA polymerase epsilon (POLE) mutations; the majority of them had GI origins. Around 144 individuals who had only received one dosage of the medication were included in the safety study, whereas those with quantifiable illness at baseline were included in the efficacy analysis at the 6-month follow-up (106 DMMR patients). The study's findings revealed that out of 106 patients, 99, or 93.4%, had gastrointestinal tumours. Additionally, the full response rate was approximately 7.5%, while the confirmed ORR in DMMR patients was around 38.7%. While median DOR was not obtained, the

median follow-up time was 12.4 months. Additionally, 68.8% of patients had treatment-related adverse events (TRAEs), of which 8.3% had at least one grade ≥ 3 TRAE, the most prevalent of which was a rise in lipase, occurring in 1.4% of patients (two patients). In addition, no deaths were brought on by the usage of drugs, and only two patients stopped taking them because to TRAE. These study findings provide evidence of dostarlimab potential anticancer efficacy against solid tumours. Finally, other cohorts in GARNET had their safety profiles examined, and the findings were highly consistent with little to no immune-related TRAEs [26-28]. Sarcomas are malignant solid tumours with a high degree of heterogeneity that accounts for the more than 100 subtypes identified to far. Chemotherapy and surgery have been demonstrated to be an efficient therapeutic method over time, leading to a somewhat higher overall survival percentage. Additionally, dostarlimab is being used to research how it works against sarcomas. TSR-042 (dostarlimab) was tested in a phase II, single-arm, non-randomized, European multicentric study of patients with advanced/metastatic clear cell sarcoma. On February 19, 2021, the trial was launched, and about 16 patients were enrolled [29].

Trials of Dostarlimab and Other Combination Therapies

Other immune check point inhibitors used in the treatment of cancer include nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab (Table 1). Dostarlimab is a mAb and not a cytokine modulator or a drug transporter substrate, hence it is unlikely to interact with other medications. To have a complete and accurate understanding, dostarlimab's pharmacodynamics and pharmacokinetic characteristics must be compared to those of other immune checkpoint inhibitor-based treatments. While atezolizumab, durvalumab, and avelumab not only work through anti-PD-1 receptors but also disrupt interaction with the PD-1 and B7.1 receptors, dostarlimab specifically targets anti-PD-1 receptors, similar to nivolumab and pembrolizumab. Similar to dostarlimab, nivolumab has a mean peak occupancy between 70 and 97 percent and about 90 percent for dostarlimab. These medications' cumulative



doses have also been noted: about 2-fold for dostarlimab, 3.7-fold for nivolumab, 2.2-fold for pembrolizumab, roughly 1.91-fold for atezolizumab, and 4.3-fold and 1.25-fold, respectively, for durvalumab and avelumab. The three-week dosing schedule guarantees that patients are closely monitored as they start a new treatment and is the same for pembrolizumab and nivolumab dose schedules. Dostarlimab is often given as part of a safety regimen at a dose of 500 mg IV every 3 weeks, followed by 1000 mg IV every 6 weeks, whilst nivolumab and pembrolizumab are given at a dose of 240 mg IV every 2 weeks and 200 mg IV every 3 weeks, respectively. Atezolizumab is similarly provided at 1200 mg or 15 mg/kg IV every three weeks, durvalumab at 1500 mg IV every four weeks, and ICI avelumab at 10 mg/kg IV every two weeks. In a combined study, dostarlimab, an anti-PD-1 monoclonal antibody, and the PARP inhibitor niraparib were both given to patients with advanced head and neck squamous cell carcinoma (HNSCC). The targeted medication known as niraparib prevents an enzyme called poly adenosine diphosphate-ribose polymerase (PARP) from repairing damaged DNA. By preventing DNA repair, blocking these PARP may cause malignant cells to perish. On February 8, 2021, this phase II experiment involving 49 individuals got underway [30]. Combinatory immunotherapy, according to research, may lower the rates of distant metastasis (DM) and loco-regional recurrence (LRR) in patients at high risk for HNSCC [31]. Similar to this, a phase III trial was created to examine the effectiveness of dostarlimab and niraparib in the treatment of high-risk neuroendocrine carcinomas and small cell lung cancer. On February 1, 2021, this single-group open-label experiment got underway with an estimated 48 patients enrolled [32]. Dostarlimab and niraparib are being tested in various phase II trials for patients with pancreatic cancer who have germline or somatic BRCA1/2- and PALB2-mutations [33], breast cancer who have BRCA mutations [34], paediatric solid tumours [35], mesothelium NSCLC [36,37], pancreatic [38], endometrial [39,40], or ovarian cancer [41,42]. Other combinations for treating NSCLC are also being researched, including cobolimab, docetaxel, and dostarlimab [43], dostarlimab and pembrolizumab [43], feladilimab,

dostarlimab, and cobolimab [44], bevacizumab, carboplatin, cobolimab, dostarlimab, niraparib, paclitaxel, and pemetrexe Dostarlimab, cobolimab, nivolumab, encelimumab, and docetaxel [47], B intrafusp alfa, cobolimab, dostarlimab, feladilimab, GSK 3174998, and pembrolizumab [48], as well as dostarlimab and encelimumab [49], are also being researched for additional colorectal and solid tumours. More encouraging developments can be made about the safety and effectiveness of both monotherapy and combination action once interim study findings are available.

Table -2 Dostarlimab Major Clinical Trial

Phase of Trials	Drug Combination	Neoplasm Type	Beginning Date	Ending Date	No. of Volunteers	Ref.
Phase II	Dostralinab	Colorectal Cancer	11/12/2019	30/11/2025	30	18
Phase I	Dostralinab	Endometrial Cancer	15/10/2019	31/10/2024	12	50
Phase II	Dostralinab	Cervical Cancer	28/6/2019	12/2024	132	25
Phase II	Dostralinab	Advanced clear cell sarcoma	19/02/2021	01/05/2024	16	29
Phase II	Dostralinab	Endometrial Cancer	02/04/2021	02/2023	31	51
Phase I	Dostralinab	Advanced solid Tumor	25/06/2020	29/08/2024	178	52
Phase I	Dostralinab	Advanced Solid Tumor	07/03/2016	30/07/2024	740	53
Phase II	Dostralinab ,niraparib	Head and neck Squamous cell Carcinoma	08/02/2021	06/2028	49	30
Phase II	Dostralinab ,niraparib	Neuroendocrine Carcinomas	1/02/2021	30/05/2025	48	32
Phase II	Dostralinab ,niraparib	Pancreatic Cancers	28/12/2020	01/12/2022	20	33
Phase II	Dostralinab ,niraparib	BRCA-mutated breast cancer	18/12/2020	17/07/2029	62	34
Phase I	Dostralinab ,niraparib	Pediatric Solid Tumor	06/10/2020	15/03/2030	116	35
Phase II	Dostralinab ,niraparib	Pancreatic Cancers	23/07/2020	01/10/2026	25	38
Phase II/III	Dostralinab ,niraparib	Endometrial and Ovarian Cancer	15/07/2020	06/2025	196	40
Phase II	Dostralinab ,niraparib, pembrolizum-ab	SCC, NSCLC	29/09/2017	31/08/2021	53	46
Phase I	Dostralinab, cobolimab, Nivolumab, encelimumab, Docetaxel	Solid tumor	08/07/2016	3/10/2024	369	47
Phase I	Dostralinab, Cobolimab, bintrafuspalfa, feladilimab, GSK 3174998, pembrolizum-ab	Solid tumor	23/06/2016	20/06/2023	829	48
Phase I	Dostralinab, Cobolimab, bintrafuspalfa, feladilimab, GSK 3174998, pembrolizum-ab	Solid tumor	23/06/2016	20/06/2023	829	48
Phase II	Dostralinab ,niraparib	Head and Neck SCC	04/11/2020	01/06/2027	23	54
Phase I	Dostralinab ,paclitaxel encegidar	Breast Cancer	01/03/2010	12/2031	4000	55
Phase II	Dostralinab ,niraparib	Mesothelium	28/01/2019	31/03/2021	200	56
Phase III	Dostralinab ,niraparib, vevacizumab	Ovarian Cancer	15/11/2018	31/03/2026	125	57
Phase III	Dostralinab ,niraparib, doxorubicin, paclitaxel,ge-citabine, Topotecan, bevacizumab	Fallopian tube and ovarian Cancer	1/12/2020	01/01/2025	427	58
Phase I/II	Dostralinab ,belantamab, mafodotin	Multiple myeloma	07/10/2019	23/02/2028	464	59
Phase II	Dostralinab, cobolimab	Melanoma	30/04/2020	10/2027	56	60
Phase III	Dostralinab ,carboplatin, paclitaxel	Endometrial Cancer	18/07/2019	23/12/2026	785	61

Conclusion

The quick remission of cancerous cells could be accelerated by activating the patient's own immune system to fight the deadly disease. The T-cell often becomes "on" after a virus enters



the body or when a given stimulus fails to have an effect, activating the body's immune system to defend itself. The immune response button of T-cells is thus "turned off" by cancer cells, preventing them from detecting and suppressing the cancer cells. As a result, immunotherapy targets tumours and prevents them from acting on T cells. One immune checkpoint inhibitor, dostarlimab, prevents the PD-1 protein on T cells from interacting to its ligand, PD-L1/2. A subset of 12 individuals with colorectal cancer and a mismatch repair defect participated in the clinical trial (MMRd). Radiation or chemotherapy, however, have little effect on these tumours. However, in the aforementioned trial, every single one of the 12 patients was entirely cured, indicating that immunotherapy may end up being a significant turning point in the development of cancer treatment. It is important to remember that all of the patients had the same disease stage and had not received any prior chemotherapy or surgical treatment. Although this group seems to respond well to the treatment, it is still impossible to predict if similar results would be seen in larger populations of people. To precisely assess the potency of dostarlimab, diverse samples should be used in a phase 3 clinical trial. Additionally, investigations on various cancer kinds could be conducted in various places.

Acknowledgments

The review paper presented gives a good knowledge of the topic based on cancer drug. In the paper firstly I would like to thank Mr. Vipin Kesharwani, Assistant Professor of Maharishi School of Pharmaceutical Sciences for completely guiding me to write this paper. Then after that I would like to thank Mr. Pankaj Jaiswal, Shailesh Pathak and Asad Farooqi for helping me in this paper. After that my colleague Anupama Singh helped me in reviewing the paper and then compiling it. I Shashank Patel has done all the work related to this review article with the help of my teachers and I have prepared the data and designed figures along with tables.

All authors approved the paper.

Reference

- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. *CA Cancer J. Clin.* **2022**, *72*, 7–33.
- From the Past, to the Present, to the Future. *Curr. Oncol.* **2020**, *27* (Suppl. 2), S87–S97.
- Singh, S.; Hassan, D.; Aldawsari, H.M.; Molugulu, N.; Shukla, R.; Kesharwani, P. Immune checkpoint inhibitors: A promising anti-cancer therapy. *Drug Discov. Today* **2019**, *25*, 223–229.
- Shukla, A.; Mishra, V.; Kesharwani, P. Bilosomes in the context of oral immunization: Development, challenges and opportunities. *Drug Discov. Today* **2016**, *21*, 888–899.
- Singh, S.; Numan, A.; Maddiboyina, B.; Arora, S.; Riadi, Y.; Shadab; Alhakamy, N.A.; Kesharwani, P. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. *Drug Discov. Today* **2021**, *26*, 1721–1727.
- Huang, P.-W.; Chang, J.W.-C. Immune checkpoint inhibitors win the 2018 Nobel Prize. *Biomed. J.* **2019**, *42*, 299–306.
- Yu, X.; Gao, R.; Li, Y.; Zeng, C. Regulation of PD-1 in T Cells for Cancer Immunotherapy. *Eur. J. Pharmacol.* **2020**, *881*, 173240.
- Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Lamendola-Essel, M.; El Dika, I.H.; Segal, N.; Shcherba, M.; Sugarman, R.; et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. *N. Engl. J. Med.* **2022**, *386*, 2363–2376.
- Kumar, S.; Ghosh, S.; Sharma, G.; Wang, Z.; Kehry, M.R.; Marino, M.H.; Neben, T.Y.; Lu, S.; Luo, S.; Roberts, S.; et al. Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD-1 Antibody with Potent Activity to Enhance Immune Function in in Vitro Cellular Assays and in Vivo Animal Models. *MAbs* **2021**, *13*, 1954136.
- Bowers, P.M.; Neben, T.Y.; Tomlinson, G.L.; Dalton, J.L.; Altobelli, L.; Zhang, X.; Macomber, J.L.; Wu, B.F.; Toobian, R.M.; McConnell, A.D.; et al. Humanization of Antibodies Using Heavy Chain Complementarity-Determining Region 3 Grafting Coupled with in Vitro Somatic Hypermutation. *J. Biol. Chem.* **2013**, *288*, 7688–7696.
- Park, U.B.; Jeong, T.J.; Gu, N.; Lee, H.T.; Heo, Y.S. Molecular Basis of PD-1 Blockade by Dostarlimab, the FDA-Approved Antibody for Cancer Immunotherapy. *Biochem. Biophys. Res. Commun.* **2022**, *599*, 31–37
- Patnaik, A.; Weiss, G.J.; Rasco, D.W.; Blaydorn, L.; Mirabella, A.; Beeram, M.; Guo, W.; Lu, S.; Danaee, H.; McEachern, K.; et al. Safety, Antitumor Activity, and Pharmacokinetics of Dostarlimab, an Anti-PD-1, in Patients with Advanced Solid Tumors: A Dose-Escalation Phase 1 Trial. *Cancer Chemother. Pharmacol.* **2022**, *89*, 93–103.
- Lu, S.; Bowsher, R.R.; Clancy, A.; Rosen, A.; Zhang, M.; Yang, Y.; Koeck, K.; Gao, M.; Potocka, E.; Guo, W.; et al. An Integrated Analysis of Dostarlimab Immunogenicity. *AAPS J.* **2021**, *23*, 96.
- Lu, S.; Bowsher, R.R.; Clancy, A.; Rosen, A.; Zhang, M.; Yang, Y.; Koeck, K.; Gao, M.; Potocka, E.; Guo, W.; et al. An Integrated Analysis of Dostarlimab Immunogenicity. *AAPS J.* **2021**, *23*, 1–12.
- Every Single Patient in This Small Experimental Drug Trial Saw Their Cancer Disappear. (n.d.). Available online: <https://www.sciencealert.com/every-single-patient->



- in-this-small-experimental-drug-trial-saw-their-cancer-disappear (accessed on 16 June 2022).
- DeWilt, J.; Vermaas, M.; Ferenschild, F.; Verhoef, C. Management of Locally Advanced Primary and Recurrent Rectal Cancer. *Clin. Colon Rectal Surg.* **2007**, *20*, 255–264.
- Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Lamendola-Essel, M.; El Dika, I.; Segal, M.; Shcherba, M.; Sugarman, R.; et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. *N. Engl. J. Med.* **2022**, *386*, 2363–2376.
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors—Full Text View—clinicaltrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04165772> (accessed on 15 June 2022).
- Kasherman, L.; Ahrari, S.; Lheureux, S. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. *Futur. Oncol.* **2021**, *17*, 877–892.
- Redondo, A.; Gallego, A.; Mendiola, M. Dostarlimab for the treatment of advanced endometrial cancer. *Expert Rev. Clin. Pharmacol.* **2022**, *15*, 1–9.
- Oaknin, A.; Tinker, A.V.; Gilbert, L.; Samouëlian, V.; Mathews, C.; Brown, J.; Barretina-Ginesta, M.-P.; Moreno, V.; Gravina, A.; Abdeddaim, C.; et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. *JAMA Oncol.* **2020**, *6*, 1766–1772.
- FDA Grants Accelerated Approval to Dostarlimab-Gxly for dMMR Endometrial Cancer | FDA, (n.d.). Available online: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxlydmmr-endometrial-cancer> (accessed on 15 June 2022).
- Oaknin, A.; Gilbert, L.; Tinker, A.V.; Brown, J.; Mathews, C.; Press, J.; Sabatier, R.; O'Malley, D.M.; Samouëlian, V.; Boni, V.; et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: Interim results from GARNET—A phase I, single-arm study. *J. Immunother. Cancer* **2022**, *10*, e003777.
- Oaknin, A.; Iglesias, M.; Alarcon, J.; Javierre, G.V.; Garcia, L.G.; Santaballa, A.; Manso, L.; Romero, I.; Ginesta, M.B.; Churrua, C.; et al. 880TiP Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation: ATOMICC study. *Ann. Oncol.* **2020**, *31*, S645.
- TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer after Chemoradiation (ATOMICC)—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03833479> (accessed on 16 June 2022).
- Andre, T.; Berton, D.; Curigliano, G.; Ellard, S.; Pérez, J.M.T.; Arkenau, H.-T.; Abdeddaim, C.; Moreno, V.; Guo, W.; Im, E.; et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. *J. Clin. Oncol.* **2021**, *39*, 9.
- FDA Grants Accelerated Approval to Dostarlimab-Gxly for dMMR Advanced Solid Tumors|FDA, (n.d.). Available online: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxlydmmr-advanced-solid-tumors> (accessed on 15 June 2022).
- Berton, D.; Banerjee, S.N.; Curigliano, G.; Cresta, S.; Arkenau, H.-T.; Abdeddaim, C.; Kristeleit, R.S.; Redondo, A.; Leath, C.A.; Torres, A.A.; et al. Antitumor activity of dostarlimab in patients with mismatch repair deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study. *J. Clin. Oncol.* **2021**, *39*, 2564.
- Study on TSR-042 in Advanced Clear Cell Sarcoma—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04274023> (accessed on 15 June 2022).
- Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-Negative HNSCC—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04681469> (accessed on 16 June 2022).
- Swaminathan, S.; Padmapriyadarsini, C.; Venkatesan, P.; Narendran, G.; Kumar, S.R.; Iliayas, S.; Menon, P.A.; Selvaraju, S.; Pooranagangadevi, N.P.; Bhavani, P.K.; et al. Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial. *Clin. Infect. Dis.* **2011**, *53*, 716–724.
- Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas— Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04701307> (accessed on 16 June 2022).
- Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer—Full Text View—Clinical Trials. gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04493060> (accessed on 16 June 2022).
- Niraparib + TSR042 In BRCA Mutated Breast Cancer—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04584255> (accessed on 16 June 2022).
- Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants with Solid Tumors (SCOOP)— Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04544995> (accessed on 16 June 2022).
- Clinical Trials Register, (n.d.). Available online: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000109-10/IT> (accessed on 16 June 2022).
- Passiglia, F.; Bironzo, P.; Righi, L.; Listì, A.; Arizio, F.; Novello, S.; Volante, M.; Scagliotti, G.V. A Prospective Phase II Singlearm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. *Clin. Lung Cancer* **2020**, *22*, e63–e66.



- Niraparib + Dostarlimab + RT in Pancreatic Cancer—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04409002> (accessed on 16 June 2022).
- Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03016338> (accessed on 16 June 2022).
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03651206> (accessed on 16 June 2022).
- A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03602859> (accessed on 16 June 2022).
- Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants with Platinum Resistant Ovarian Cancer—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03955471> (accessed on 16 June 2022).
- Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04581824> (accessed on 16 June 2022).
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants with Non-Small Cell Lung Cancer (NSCLC)—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03739710> (accessed on 16 June 2022).
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination with TSR-042—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://www.clinicaltrials.gov/ct2/show/NCT03307785> (accessed on 16 June 2022).
- Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03308942> (accessed on 16 June 2022).
- A Study of TSR-022 in Participants with Advanced Solid Tumors (AMBER)—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT02817633> (accessed on 16 June 2022).
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT02723955> (accessed on 16 June 2022).
- Study of TSR-033 with an Anti-Programmed Cell Death-1 Receptor (PD-1) in Participants with Advanced Solid Tumors—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03250832> (accessed on 16 June 2022).
- TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer—Full Text View—clinicaltrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03955978> (accessed on 16 June 2022).
- Radiation and TSR-042 in People With Endometrial Cancer After They Receive Surgery—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04774419> (accessed on 16 June 2022).
- Study of the Safety and Effectiveness of GSK6097608 in Participants with Advanced Solid Tumors—Full Text—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04446351> (accessed on 16 June 2022).
- Study of TSR-042, an Anti-Programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants with Advanced Solid Tumors—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT02715284> (accessed on 16 June 2022).
- Study of TSR-042, an Anti-Programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants with Advanced Solid Tumors—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT02715284> (accessed on 16 June 2022).
- SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT01042379> (accessed on 16 June 2022).
- Mesothelioma Stratified Therapy (MiST): A Multi-Drug Phase II Trial in Malignant Mesothelioma—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03654833> (accessed on 16 June 2022).
- A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants with Ovarian Cancer—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT03574779> (accessed on 16 June 2022).
- Trial on Niraparib-TSR-042 (Dostarlimab) vs Physician's Choice Chemotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04679064> (accessed on 16 June 2022).
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)—Full Text View—ClinicalTrials.gov, (n.d.). Available online: <https://clinicaltrials.gov/ct2/show/NCT04126200> (accessed on 16 June 2022).
- Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042), vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022)



and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma—Full Text View—ClinicalTrials.gov, (n.d). Available online: <https://clinicaltrials.gov/ct2/show/NCT04139902> (accessed on 16 June 2022).

- A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-Paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer—Full Text View—ClinicalTrials.gov, (n.d). Available online: <https://clinicaltrials.gov/ct2/show/NCT03981796> (accessed on 16 June 2022).